Fusion Pharmaceuticals (Fusion Pharmaceuticals) Cash Flow from Financing : $142.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Fusion Pharmaceuticals received $57.27 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.59 Mil on other financial activities. In all, Fusion Pharmaceuticals earned $57.86 Mil on financial activities for the three months ended in Dec. 2023.

Fusion Pharmaceuticals Cash Flow from Financing Historical Data

The historical data trend for Fusion Pharmaceuticals's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals Cash Flow from Financing Chart

Fusion Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

52.19

265.51

0.35

40.73

142.01

Fusion Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Financing	Get a 7-Day Free Trial															0.13	59.52	24.31	0.33	57.86

Fusion Pharmaceuticals Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Fusion Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	145.125	+	0	+	0	+	0	+	0	+	-3.119
=	142.01

Fusion Pharmaceuticals's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	57.266	+	0	+	0	+	0	+	0	+	0.589
=	57.86

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $142.01 Mil.

Fusion Pharmaceuticals (NAS:FUSN) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Fusion Pharmaceuticals's issuance of stock for the three months ended in Dec. 2023 was $57.27 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Fusion Pharmaceuticals's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Fusion Pharmaceuticals's net issuance of debt for the three months ended in Dec. 2023 was $0.00 Mil. Fusion Pharmaceuticals received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Fusion Pharmaceuticals's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Fusion Pharmaceuticals paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Fusion Pharmaceuticals's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Fusion Pharmaceuticals received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Fusion Pharmaceuticals's other financing for the three months ended in Dec. 2023 was $0.59 Mil. Fusion Pharmaceuticals received $0.59 Mil on other financial activities.

Fusion Pharmaceuticals Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6

Website

https://www.fusionpharma.com

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Executives

Teresa Marie Bitetti	director	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender	director	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev	officer: Chief Medical Officer	C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant	director, officer: Chief Executive Officer	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon	officer: Chief Scientific Officer	C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat	officer: President and CBO	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom	director	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee	director	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley	officer: Chief Financial Officer	251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p.	10 percent owner	18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary	officer: Chief Medical Officer	830 WINTER STREET, WALTHAM MA 02452